ProKidney Corp. (PROK) Stock Analysis
A live, multi-source view of ProKidney Corp. (PROK): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Sector: Healthcare · Industry: Biotechnology · United States · 231 employees · prokidney.com
Key statistics · as of 2026-09-06
As of 2026-09-06, ProKidney Corp. (PROK) had a market capitalization of $802.4M (forward -3.4) and a beta of 1.75; the shares traded in a 52-week range of $1.30 – $3.48 (-6.9% over the year).
- Market cap
- $802.4M
- Enterprise value
- $1.35B
- Forward P/E
- -3.4
- EPS (trailing)
- $-0.55
- EPS (forward)
- $-0.59
- Payout ratio
- 0.0%
- 52-week range
- $1.30 – $3.48
- 52-week change
- -6.9%
- Beta
- 1.75
- Average volume
- 1.2M
- Shares outstanding
- 208.9M
- Short % of float
- 13.83%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, ProKidney Corp. (PROK) last closed at $1.85 (the last completed close before that scan).
Technicals at the scan: RSI 57 (neutral territory), price +10.1% versus its 20-day average, 20-day versus 50-day average spread 0.0%, MACD histogram 0.03.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 57/100.
Next scheduled company event: in 60 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of PROK; corporate insiders filed 0 buys and 6 sells (1 filer, latest disclosure 2026-08-20). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Brian Jg Pereira (0B/6S). Who is trading what
RapidTradeView pick record
PROK has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls ProKidney Corp. (PROK) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PROK.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.